Inside USP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP

Control Strategies for Synthetic Therapeutic Peptide APIs— Part I: Analytical Consideration

March 2, 2014

Pharmaceutical Technology

USP evaluates quality attributes for synthetic peptides.

USP Seeks Input on Standards for Plastic Packaging Systems

October 2, 2013

Pharmaceutical Technology

USP seeks input from stakeholders on new and revised standards to mitigate extractables and leachables in plastic packaging systems.

USP Partners Globally for 21st-Century Medicines

July 2, 2013

Pharmaceutical Technology

USP focuses on building worldwide partnerships in standards-setting activities.

Moisture Permeation of Pharmaceutical Packaging

April 2, 2013

Pharmaceutical Technology

USP is proposing a new performance testing standard for moisture permeation of pharmaceutical packaging.

Modernization of USP Standards

February 2, 2013

Pharmaceutical Technology

The US Pharmacopeial Convention contiues to make modernization of standards a top priority in 2013.

USP Further Strengthens Quality Standards for Heparin

September 2, 2012

Pharmaceutical Technology

USP optimizes identification tests and impurities procedures.

Inside USP: US Pharmacopeia Proposes New Standard on Glass Quality

June 2, 2012

Pharmaceutical Technology

US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.

Inside USP: A Holistic Approach to Supply-Chain Integrity

March 2, 2012

Pharmaceutical Technology

US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.

Inside USP: Global Harmonization Presents Opportunities and Challenges

January 2, 2012

Pharmaceutical Technology

To keep moving forward, the Pharmacopoeial Discussion Group needs industry participation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here